KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biolife Solutions (BLFS) EPS (Weighted Average and Diluted) (2017 - 2025)

Biolife Solutions (BLFS) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with $0.23 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 14.81% to $0.23 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.1, a 9.09% increase, with the full-year FY2025 number at -$0.1, up 77.27% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.23 for Q4 2025 at Biolife Solutions, up from $0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.15 in Q4 2022 to a low of -$1.72 in Q2 2022.
  • A 5-year average of -$0.06 and a median of -$0.08 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 850.0% in 2021, then tumbled 1005.26% in 2022.
  • Biolife Solutions' EPS (Weighted Average and Diluted) stood at -$0.4 in 2021, then surged by 637.5% to $2.15 in 2022, then crashed by 80.93% to $0.41 in 2023, then tumbled by 34.15% to $0.27 in 2024, then decreased by 14.81% to $0.23 in 2025.
  • Per Business Quant, the three most recent readings for BLFS's EPS (Weighted Average and Diluted) are $0.23 (Q4 2025), $0.01 (Q3 2025), and -$0.33 (Q2 2025).